EQT, a private equity firm, agreed to acquire a 13.6% stake in Karo Pharma, a pharmaceutical company, for $217m. “Having worked closely with Karo Pharma’s management, board of directors, and employees for the past three years, we believe that the company today is in a good position to enter its next phase of development. Looking ahead, we see great potential in continuing to develop Karo Pharma’s product portfolio and commercial capabilities, expanding into new markets, channels and categories and increasing investments into the platform and via M&A. However, for Karo Pharma to reach its full potential we are convinced that its continued value creation journey is best suited to a private environment," Erika Henriksson, EQT Partner.